跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,255 条关于
“miR-522”
全部
5,255
临床试验
3,760
药物
843
机构
97
资讯
555
去年
Exosomes Emerge as Dual-Purpose Tools in Cancer: From Drug Resistance Mechanisms to Therapeutic Delivery Systems
去年
CSF Biomarkers NfL, CHIT1, and miR-181b Evaluated for ALS Diagnosis and Prognosis
2年前
Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early-Stage TNBC
去年
Cleveland Clinic Reports Real-World Outcomes of KEYNOTE-522 Regimen in Triple-Negative Breast Cancer Treatment
2年前
Keytruda Demonstrates Significant Overall Survival Benefit in Early-Stage TNBC
去年
Keynote-522 Trial Demonstrates Overall Survival Benefit with Pembrolizumab in Triple-Negative Breast Cancer
去年
Sanofi Invests in Resalis Therapeutics' miRNA-22 Inhibitor for Obesity Treatment
28天前
Australian researchers uncover molecular switch driving triple-negative breast cancer metastasis, pointing to CDK4/6 inhibitor repurposing
去年
Real-World Data Shows Improved Responses with Pembrolizumab/Chemotherapy in Early-Stage TNBC
去年
HDAC Inhibition in Muscle Cells Enhances Bone Regeneration via Extracellular Vesicles
第 1 页,共 56 页
上一页
下一页